BR112012020116B8 - Anticorpo anti-p-caderina marcado com metal radioativo, agente terapêutico contra o câncer e agente de diagnóstico de câncer que compreendem o dito anticorpo, hibridoma, bem como usos do mesmo para produzir um agente terapêutico contra o câncer e um agente de diagnóstico de câncer - Google Patents

Anticorpo anti-p-caderina marcado com metal radioativo, agente terapêutico contra o câncer e agente de diagnóstico de câncer que compreendem o dito anticorpo, hibridoma, bem como usos do mesmo para produzir um agente terapêutico contra o câncer e um agente de diagnóstico de câncer

Info

Publication number
BR112012020116B8
BR112012020116B8 BR112012020116A BR112012020116A BR112012020116B8 BR 112012020116 B8 BR112012020116 B8 BR 112012020116B8 BR 112012020116 A BR112012020116 A BR 112012020116A BR 112012020116 A BR112012020116 A BR 112012020116A BR 112012020116 B8 BR112012020116 B8 BR 112012020116B8
Authority
BR
Brazil
Prior art keywords
cancer
antibody
therapeutic agents
diagnostic
agents against
Prior art date
Application number
BR112012020116A
Other languages
English (en)
Other versions
BR112012020116A2 (pt
BR112012020116B1 (pt
Inventor
Hino Akihiro
Nagano Akio
Watanabe Masahiko
Matsuura Tadasi
Satoh Hirokazu
Nomura Fumiko
Mitomo Katsuyuki
Original Assignee
Perseus Proteomics Inc
Fujifilm Ri Pharma Co Ltd
Fujifilm Toyama Chemical Co Ltd
Ftp Co Ltd
Pdradiopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perseus Proteomics Inc, Fujifilm Ri Pharma Co Ltd, Fujifilm Toyama Chemical Co Ltd, Ftp Co Ltd, Pdradiopharma Inc filed Critical Perseus Proteomics Inc
Publication of BR112012020116A2 publication Critical patent/BR112012020116A2/pt
Publication of BR112012020116B1 publication Critical patent/BR112012020116B1/pt
Publication of BR112012020116B8 publication Critical patent/BR112012020116B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

ANTICORPO ANTI-CADERINA MARCADO COM METAL RADIOATIVO. Um objetivo da presente invenção consiste e proporcionar um anticorpo anti-caderina de metal radioativo que seja altamente acumulado especificamente em tecido cancerígeno. Outro Objetivo consiste em proporcionar um agente terapêutico contra câncer tendo um alto efeito anticancerígeno e segurança e um agente de diagnóstico de câncer. O anticorpo anti-caderina marcado com metal radioativo é obtido ligando-se um elemento metálico radioativo a um anticorpo anti-caderina através de um reagente quelante metálico.
BR112012020116A 2010-02-10 2011-02-09 Anticorpo anti-p-caderina marcado com metal radioativo, agente terapêutico contra o câncer e agente de diagnóstico de câncer que compreendem o dito anticorpo, hibridoma, bem como usos do mesmo para produzir um agente terapêutico contra o câncer e um agente de diagnóstico de câncer BR112012020116B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010028028 2010-02-10
JP2010-028028 2010-02-10
PCT/JP2011/052759 WO2011099524A1 (ja) 2010-02-10 2011-02-09 放射性金属標識抗カドヘリン抗体

Publications (3)

Publication Number Publication Date
BR112012020116A2 BR112012020116A2 (pt) 2020-08-18
BR112012020116B1 BR112012020116B1 (pt) 2021-12-14
BR112012020116B8 true BR112012020116B8 (pt) 2023-01-10

Family

ID=44367795

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012020116A BR112012020116B8 (pt) 2010-02-10 2011-02-09 Anticorpo anti-p-caderina marcado com metal radioativo, agente terapêutico contra o câncer e agente de diagnóstico de câncer que compreendem o dito anticorpo, hibridoma, bem como usos do mesmo para produzir um agente terapêutico contra o câncer e um agente de diagnóstico de câncer

Country Status (22)

Country Link
US (2) US8815211B2 (pt)
EP (1) EP2535358B1 (pt)
JP (2) JP5380553B2 (pt)
KR (1) KR101900110B1 (pt)
CN (1) CN102892787B (pt)
AU (1) AU2011215267B2 (pt)
BR (1) BR112012020116B8 (pt)
CA (1) CA2789310C (pt)
CY (1) CY1120012T1 (pt)
DK (1) DK2535358T3 (pt)
ES (1) ES2656168T3 (pt)
HR (1) HRP20180293T1 (pt)
HU (1) HUE037817T2 (pt)
LT (1) LT2535358T (pt)
NO (1) NO2535358T3 (pt)
PL (1) PL2535358T3 (pt)
PT (1) PT2535358T (pt)
RS (1) RS57008B1 (pt)
RU (1) RU2577125C2 (pt)
SG (1) SG183272A1 (pt)
SI (1) SI2535358T1 (pt)
WO (1) WO2011099524A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2789310C (en) * 2010-02-10 2018-01-09 Fujifilm Ri Pharma Co., Ltd. Radioactive metal-labeled anti-cadherin antibody
US9127061B2 (en) * 2011-06-24 2015-09-08 Perseus Proteomics Inc. Anti-human P-cadherin (CDH3) recombinant antibody
WO2013039111A1 (ja) * 2011-09-16 2013-03-21 株式会社 島津製作所 病変部位の内照射治療用ナノ粒子及び治療システム
KR20150003251A (ko) 2012-04-04 2015-01-08 가부시키가이샤 페르세우스 프로테오믹스 항 cdh3(p-카드헤린) 항체의 약물 콘쥬게이트
BR112015019328A2 (pt) * 2013-02-15 2017-08-22 Perseus Proteomics Inc Anticorpo anti-cdh3 humanizado, conjugado do fármaco do anticorpo anti-cdh3 humanizado, e seu uso
WO2015181882A1 (ja) * 2014-05-27 2015-12-03 株式会社島津製作所 分岐型両親媒性ブロックポリマーを用いた分子集合体及び薬剤搬送システム
JP2017520575A (ja) 2014-07-01 2017-07-27 ファイザー・インク 二重特異的ヘテロ二量体ダイアボディおよびその使用
JP6831783B2 (ja) 2014-11-14 2021-02-17 ノバルティス アーゲー 抗体薬物コンジュゲート
EP3400013A4 (en) * 2016-01-09 2019-09-11 Arbele Limited CADHERIN-17 SPECIFIC ANTIBODIES AND CYTOTOXIC CELL TREATMENT CELLS
WO2018034354A1 (ja) * 2016-08-19 2018-02-22 富士フイルムＲｉファーマ株式会社 緩衝剤を含む組成物
RU2657761C1 (ru) * 2017-05-29 2018-06-15 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Томский политехнический университет" Способ диагностики опухоли

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4917878A (en) * 1988-05-02 1990-04-17 Thomas Jefferson University Novel use of a radiolabelled antibody against stage specific embryonic antigen for the detection of occult abscesses in mammals
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
DE69333823T2 (de) 1992-03-24 2006-05-04 Cambridge Antibody Technology Ltd., Melbourn Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
CA2177367A1 (en) 1993-12-03 1995-06-08 Andrew David Griffiths Recombinant binding proteins and peptides
AU701342B2 (en) 1994-07-13 1999-01-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
KR100654645B1 (ko) 1995-04-27 2007-04-04 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO2000026672A1 (en) * 1998-10-30 2000-05-11 Georgetown University Diagnosis of breast cancer using antibody against cadherin-11
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
EP3263702A1 (en) 2000-10-06 2018-01-03 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
CA2445611A1 (en) 2001-05-31 2002-12-05 Chiron Corporation P-cadherin as a target for anti-cancer therapy
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
EP1467757B1 (en) * 2001-12-28 2008-05-07 Amgen Fremont Inc. Use of antibodies against the muc18 antigen
WO2003101495A1 (en) 2002-05-29 2003-12-11 Immunomedics, Inc. Methods and compositions for radioimmunotherapy of brain and cns tumors
EP1560597A4 (en) 2002-10-29 2007-06-27 Pharmacia Corp DIFFERENTIALLY EXPRESSED GENES INVOLVED IN CANCER, POLYPEPTIDES CODED THEREWITH, AND METHODS OF USING GENES
ITMI20022411A1 (it) 2002-11-14 2004-05-15 Bracco Imaging Spa Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate.
EP2962699A3 (en) * 2003-12-01 2016-04-06 Immunomedics Inc. Improved method for preparing conjugates of proteins and chelating agents
CN1977044A (zh) 2004-03-24 2007-06-06 肿瘤疗法科学股份有限公司 治疗胰腺癌的组合物和方法
EP1753395B1 (en) * 2004-05-24 2010-07-28 Warner Chilcott Company, LLC Enteric solid oral dosage form of a bisphosphonate containing a chelating agent
AU2006238930B2 (en) 2005-04-26 2010-12-23 Pfizer Inc. P-cadherin antibodies
CN101432303A (zh) * 2006-02-28 2009-05-13 肿瘤疗法科学股份有限公司 利用抗cdh3抗体的效应物功能来损伤细胞的方法
KR20110025215A (ko) 2008-06-30 2011-03-09 온코세라피 사이언스 가부시키가이샤 방사성 동위원소 표지로 표지된 항―ｃｄｈ３ 항체 및 이의 용도
AU2010242338B2 (en) 2009-05-01 2013-12-19 Perseus Proteomics Inc. Anti-cadherin antibody
EP2519542B1 (en) * 2009-12-28 2018-10-10 OncoTherapy Science, Inc. Anti-cdh3 antibodies and uses thereof
CA2789310C (en) * 2010-02-10 2018-01-09 Fujifilm Ri Pharma Co., Ltd. Radioactive metal-labeled anti-cadherin antibody

Also Published As

Publication number Publication date
JP5848737B2 (ja) 2016-01-27
US20130071324A1 (en) 2013-03-21
US20140328754A1 (en) 2014-11-06
EP2535358A1 (en) 2012-12-19
WO2011099524A1 (ja) 2011-08-18
PT2535358T (pt) 2018-02-23
CY1120012T1 (el) 2018-12-12
BR112012020116A2 (pt) 2020-08-18
HRP20180293T1 (hr) 2018-03-23
EP2535358B1 (en) 2017-12-20
AU2011215267A1 (en) 2012-09-06
CA2789310C (en) 2018-01-09
EP2535358A9 (en) 2014-03-26
AU2011215267B2 (en) 2016-07-07
BR112012020116B1 (pt) 2021-12-14
ES2656168T3 (es) 2018-02-23
JP5380553B2 (ja) 2014-01-08
RS57008B1 (sr) 2018-05-31
KR101900110B1 (ko) 2018-09-18
KR20120115995A (ko) 2012-10-19
CN102892787B (zh) 2015-04-29
NO2535358T3 (pt) 2018-05-19
CA2789310A1 (en) 2011-08-18
DK2535358T3 (en) 2018-02-05
LT2535358T (lt) 2018-03-26
HUE037817T2 (hu) 2018-09-28
RU2577125C2 (ru) 2016-03-10
PL2535358T3 (pl) 2018-05-30
CN102892787A (zh) 2013-01-23
SI2535358T1 (en) 2018-03-30
US8815211B2 (en) 2014-08-26
JP2014012731A (ja) 2014-01-23
JPWO2011099524A1 (ja) 2013-06-13
SG183272A1 (en) 2012-09-27
RU2012138459A (ru) 2014-03-20
EP2535358A4 (en) 2013-07-10

Similar Documents

Publication Publication Date Title
BR112012020116B8 (pt) Anticorpo anti-p-caderina marcado com metal radioativo, agente terapêutico contra o câncer e agente de diagnóstico de câncer que compreendem o dito anticorpo, hibridoma, bem como usos do mesmo para produzir um agente terapêutico contra o câncer e um agente de diagnóstico de câncer
BR112016002000A2 (pt) Diagnóstico e terapia de câncer envolvendo células-tronco tumorais
BR112012018132A2 (pt) "marcadores de células - tronco tumorais e uso dos mesmos".
AR078659A1 (es) Anticuerpos monoclonales contra progastrina humana y sus usos
ECSP12012097A (es) Derivados de fumarato de ácido graso y sus usos
MX2021008976A (es) Inhibidores marcados de antigeno prostatico especifico de membrama (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.
CR20160199A (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
CR20140357A (es) Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
BR112016000903A2 (pt) anticorpos
CR20140431A (es) Anticuerpos biespecificos contra tweak humana e il 17 humana y usos de los mismos
TR201910959T4 (tr) Elektromanyetik radyasyonun insan irisine uygulanması.
BR112013001691A2 (pt) particulados de metal geradores de corrente de corrosão e uso dos mesmos
MX2018014044A (es) Anticuerpos humanizados que reconocen alfa-sinucleina.
BR112012016820A2 (pt) Metodos para tratamento de cancer de seio
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112012026707A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado
BR112015023098A2 (pt) agentes de infrarregulação do receptor de andrógeno e usos dos mesmos
BR112017003956A2 (pt) adsorvente para ligação de metais e produção do mesmo
AR077867A1 (es) Terapia combinatoria de un anticuerpo cd20 afucosilado con fludarabina y/o mitoxantrona
BR112015023020A2 (pt) combinação de inibidor de egfr t790m e inibidor de egfr para o tratamento de câncer pulmonar de células não-pequenas
BR112016014077A2 (pt) Tratamento fotodinâmico de pulso de condições de pele
BR112015027474A8 (pt) anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo.
GT201200345A (es) Compuestos heterocìclicos, su preparaciòn y su aplicaciòn terapèutica
BR112013002441A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição e método de tratamento de paciente que sofre de câncer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/02/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B25D Requested change of name of applicant approved

Owner name: PERSEUS PROTEOMICS INC. (JP) ; FUJIFILM TOYAMA CHEMICAL CO., LTD. (JP)

B25A Requested transfer of rights approved

Owner name: PERSEUS PROTEOMICS INC. (JP) ; FTP CO., LTD (JP)

B25D Requested change of name of applicant approved

Owner name: PERSEUS PROTEOMICS INC. (JP) ; PDRADIOPHARMA INC. (JP)